



## Capital Health

Issue # 49: February, 2012

### Inside this Issue.....

Additions to Formulary – Rivaroxaban  
Pre-Printed Orders

The following policies were approved by the District Medical Advisory Committee (Nov11, Dec11) on the recommendation of the District Drugs and Therapeutics Committee (Sep11, Nov11).

## I. Additions to Formulary

### **Rivaroxaban, Xarelto®**

Rivaroxaban is an oral, selective, direct factor Xa inhibitor. Inhibiting factor Xa stops the generation of thrombin, thereby inhibiting thrombin mediated activation of coagulation. Rivaroxaban provides a fixed dose response following once daily dosing and does not require laboratory monitoring. Dosage adjustment is required in renal insufficiency.

A series of four clinical trials have evaluated the efficacy of rivaroxaban 10 mg daily in the prevention of venous thromboembolism in total hip replacement and total knee replacement surgery. Rivaroxaban was compared to enoxaparin, a low molecular weight heparin, and was associated with statistically significant reductions in the incidence of the composite outcome of deep vein thrombosis, non-fatal pulmonary embolism and all cause mortality.

The rates of major bleeding were numerically higher for rivaroxaban compared to enoxaparin in three of four trials. However, there was no statistical difference in bleeding between groups and overall the rates of major bleeding were low across treatment arms (less than 1%).

### **Approved Restriction:**

- For the prophylaxis of venous thromboembolism following total knee replacement or total hip replacement
- The dose is limited to 10 mg per day for up to two weeks.

## III. Pre-Printed Orders

The following new or revised pre-printed orders have been approved by the Medical Advisory Committee on the recommendation of the District Drugs and Therapeutics Committee.

PPO 0350 Hepatitis B Immunization for patients with CrCl less than 30 mL/min

PPO 0384 Peritoneal Dialysis Leak Protocol

PPO 0385 Peritoneal Dialysis Catheter Repositioning Protocol

PPO 0386 Home Peritoneal Dialysis Orders

PPO 0389 Peritoneal Dialysis (PD) CT Imaging Protocol

PPO 0394 Management of Peritonitis

PPO 0395 Empiric Management of Peritonitis

PPO 0397 Pneumococcal and Influenza Vaccination

PPO 0235 Request for IVIG (Adult)

PPO 0251 Bladder Cancer: Intravesical MitoMYCIN

PPO 0267 Prothrombin Complex Concentrate (Beriplex/Octiplex) Orders

PPO 0299 Pre-Cardiac Catheterization/PCI/EP Orders

PPO 0305 Cyclophosphamide Protocol for Lupus Nephritis

PPO 0362 Carboplatin-Gyne Regimen Desensitization Protocol

PPO 0365 Severe-Sepsis/Septic Shock Resuscitation

PPO 0387 Parenteral Nutrition (PN) Order

PPO 0388 Routine Bowel Care Orders

PPO 0391 Negative Pressure Wound Therapy

PPO 0393 Ketamine: Low Dose Infusion as an Adjuvant to Opioid Analgesia

PPO 0400 Management of Anticoagulation Before and After Radiology Interventional Procedures in Hemodialysis

The information contained in this newsletter may also be accessed online:

<http://cdhaintra/departmentservices/pharmacy/Formulary/index.cfm>

Published by the Pharmacy Department, Capital Health

Editor: Natasha Rodney, B.Sc. (Pharm.)  
Drug Information

Tel: (902) 473-8503

Email: natasha.rodney@cdha.nshealth.ca